Ariad Pharmaceuticals, Inc.  

(Public, NASDAQ:ARIA)   Watch this stock  
Find more results for ARIA
23.99
Feb 16 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 4.67 - 23.99
Open     -
Vol / Avg. 0.00/16.13M
Mkt cap 4.67B
P/E     -
Div/yield     -
EPS -0.18
Shares 194.20M
Beta 2.15
Inst. own 88%
Feb 21, 2017
Q4 2016 ARIAD Pharmaceuticals Inc Earnings Release (Estimated)
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -60.47% -194.57%
Operating margin -54.31% -182.89%
EBITD margin - -172.15%
Return on average assets -17.16% -40.21%
Return on average equity - -
Employees 459 -
CDP Score - -

Address

125 Binney St
CAMBRIDGE, MA 02142-1123
United States - Map
+1-617-4940400 (Phone)
+1-617-4948144 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ARIAD Pharmaceuticals, Inc. (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company's product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company's Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). Its AP32788 is a TKI, which is designed as a targeted therapy for patients with non-small cell lung cancer (NSCLC) with specific mutations in two kinases, epidermal growth factor receptor (EGFR), or human epidermal growth factor receptor 2 (HER2). Its Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).